Maynard Um
-
-
-
-
-
-
-
SAREPTA gets approval to test Huntington's disease treatment in humans
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
-
-
-
-
-
-
-
Wedbush Starts Sarepta Therapeutics (SRPT) at Outperform
-
-
-
-
-
-
-
FDA approves new safety warning and revised indication that limits use for Elevidys following reports of fatal liver injuryHHS: FDA approves new safety warning and revised indication that limits
-
-
-
-
-
-
-
Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT), 'Several Dynamics to Follow But Optics Could Further Improve in 2026'
-
-
-
-
-
-
-
Mizuho on Sarepta Therapeutics (SRPT): 'Lowering 3Q25 Elevidys Sales Below Consensus'
-
-
-
-
-
-
-
Freedom Broker Upgrades Sarepta Therapeutics (SRPT) to Buy
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

